A pre-commercial biotech reliant on R&D investment and episodic funding
Scancell has no product-sales revenue and recurring operating losses as it funds clinical and platform development. Collaboration receipts are episodic, and the history shows reliance on equity, debt, and licensing to supplement operating cash needs.